

# W Ken Redekop

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2173551/publications.pdf>

Version: 2024-02-01

59  
papers

1,769  
citations

377584

21  
h-index

312153

41  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2994  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon- $\beta$ 1a Therapy Versus Injectable Interferon- $\beta$ 1a Treatment in Relapsing-Remitting Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2022, 40, 91-108.	1.7	4
2	Gray Literature in Evaluating Effectiveness in Digital Health and Health and Welfare Technology: A Source Worth Considering. <i>Journal of Medical Internet Research</i> , 2022, 24, e29307.	2.1	7
3	Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 20, 101418.	1.7	3
4	Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States. <i>Journal of Cancer Policy</i> , 2022, 33, 100346.	0.6	3
5	A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults. <i>Value in Health</i> , 2021, 24, 325-335.	0.1	17
6	Health-related quality of life of multiple sclerosis patients: a European multi-country study. <i>Archives of Public Health</i> , 2021, 79, 39.	1.0	21
7	Innovative Medical Technology and the Treatment Decision-Making Process in Multiple Sclerosis: A Focus Group Study to Examine Patient Perspectives. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 927-937.	0.8	2
8	Nocturnal digital surveillance in aged populations and its effects on health, welfare and social care provision: a systematic review. <i>BMC Health Services Research</i> , 2021, 21, 622.	0.9	9
9	Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. <i>Pregnancy Hypertension</i> , 2021, 25, 219-224.	0.6	12
10	Mobile Safety Alarms Based on GPS Technology in the Care of Older Adults: Systematic Review of Evidence Based on a General Evidence Framework for Digital Health Technologies. <i>Journal of Medical Internet Research</i> , 2021, 23, e27267.	2.1	13
11	How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 336.	1.5	2
12	Long-Term Effects of Dexmedetomidine versus Propofol During the Implantation of a Neurostimulator—A Post-Trial Follow-Up Analysis. <i>Journal of Pain Research</i> , 2021, Volume 14, 3631-3636.	0.8	0
13	Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101929.	0.9	24
14	Trusted writing in social media: FPM International Awards for Medical Writing in Social Media. <i>Postgraduate Medical Journal</i> , 2020, 96, 183-183.	0.9	1
15	Cost-effectiveness of Mechanical Thrombectomy More Than 6 Hours After Symptom Onset Among Patients With Acute Ischemic Stroke. <i>JAMA Network Open</i> , 2020, 3, e2012476.	2.8	30
16	Future of Data Analytics in the Era of the General Data Protection Regulation in Europe. <i>Pharmacoeconomics</i> , 2020, 38, 1021-1029.	1.7	7
17	What is ahead for health policy and technology in the 2020s?. <i>Health Policy and Technology</i> , 2020, 9, 3-4.	1.3	3
18	Trusted writing in social media: FPM International Awards for Medical Writing in Social Media. <i>Health Policy and Technology</i> , 2020, 9, 5-6.	1.3	2

#	ARTICLE	IF	CITATIONS
19	What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 177-189.	0.7	0
20	Response to "Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy". <i>Pharmacoeconomics</i> , 2018, 36, 381-382.	1.7	0
21	Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e131-e142.	0.2	22
22	Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. <i>Pharmacoeconomics</i> , 2018, 36, 91-103.	1.7	26
23	Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. <i>PLoS ONE</i> , 2018, 13, e0205079.	1.1	3
24	The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 325-335.	0.6	4
25	Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 697-706.	1.0	8
26	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 179.	1.2	15
27	Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges. <i>Frontiers in Pharmacology</i> , 2016, 7, 113.	1.6	10
28	Individualized Angiotensin-Converting Enzyme (ACE) Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model. <i>Journal of the American Heart Association</i> , 2016, 5, e002688.	1.6	16
29	Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. <i>Value in Health</i> , 2016, 19, 834-843.	0.1	18
30	Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results " a case study. <i>BMC Health Services Research</i> , 2015, 16, 23.	0.9	1
31	A conceptual disease model for adult Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 112.	1.2	10
32	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	0.8	28
33	Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. <i>BMJ Open</i> , 2015, 5, e007241.	0.8	3
34	Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 557-559.	0.7	13
35	DRG systems in Europe: variations in cost accounting systems among 12 countries. <i>European Journal of Public Health</i> , 2014, 24, 1023-1028.	0.1	43
36	Tools and Techniques - Statistics: Comments on a cost-effectiveness study of TAVI for patients with inoperable aortic stenosis. <i>EuroIntervention</i> , 2014, 9, 1241-1243.	1.4	0

#	ARTICLE	IF	CITATIONS
37	The Faces of Personalized Medicine: A Framework for Understanding Its Meaning and Scope. <i>Value in Health</i> , 2013, 16, S4-S9.	0.1	138
38	Current Methodological Issues in the Economic Assessment of Personalized Medicine. <i>Value in Health</i> , 2013, 16, S20-S26.	0.1	70
39	The Economic Evaluation of Medical Devices. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 15-26.	1.0	43
40	Systematic Review of the Accuracy of Dual-Source Cardiac CT for Detection of Arterial Stenosis in Difficult to Image Patient Groups. <i>Radiology</i> , 2013, 267, 387-395.	3.6	48
41	Differences in Quality of Antenatal Care Provided by Midwives to Low-Risk Pregnant Dutch Women in Different Ethnic Groups. <i>Journal of Midwifery and Women's Health</i> , 2012, 57, 461-468.	0.7	1
42	Ethnic differences in antenatal care use in a large multi-ethnic urban population in the Netherlands. <i>Midwifery</i> , 2011, 27, 36-41.	1.0	29
43	A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. <i>Quality of Life Research</i> , 2011, 20, 875-887.	1.5	75
44	Diabetes Prevalence in Populations of South Asian Indian and African Origins. <i>Epidemiology</i> , 2011, 22, 563-567.	1.2	57
45	Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes. <i>Value in Health</i> , 2010, 13, 138-147.	0.1	28
46	Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach. <i>Patient Preference and Adherence</i> , 2010, 4, 283.	0.8	7
47	A Cross-National Comparative Study of Blood Pressure and Hypertension Between English and Dutch South-Asian- and African-Origin Populations: The Role of National Context. <i>American Journal of Hypertension</i> , 2010, 23, 639-648.	1.0	48
48	Comparing Methodologies for the Allocation of Overhead and Capital Costs to Hospital Services. <i>Value in Health</i> , 2009, 12, 530-535.	0.1	23
49	Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland. <i>Pharmacoeconomics</i> , 2008, 26, 861-877.	1.7	5
50	Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 41-48.	0.7	6
51	Acute Abdominal Aortic Aneurysms: Cost Analysis of Endovascular Repair and Open Surgery in Hemodynamically Stable Patients with 1-year Follow-up. <i>Radiology</i> , 2006, 240, 681-689.	3.6	18
52	Cost-Effectiveness of Prevention and Treatment of the Diabetic Foot: A Markov analysis. <i>Diabetes Care</i> , 2004, 27, 901-907.	4.3	149
53	The Cost Effectiveness of Apligraf Treatment of Diabetic Foot Ulcers. <i>Pharmacoeconomics</i> , 2003, 21, 1171-1183.	1.7	63
54	Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 458-463.	4.3	435

#	ARTICLE	IF	CITATIONS
55	Cost-utility analysis of patient care in children with meningeal signs. International Journal of Technology Assessment in Health Care, 2002, 18, 485-96.	0.2	22
56	The Cost of Treatment of Alzheimer??s Disease in The Netherlands. Pharmacoeconomics, 2001, 19, 379-390.	1.7	26
57	Cost Effectiveness of Continuous Terbinafine Compared with Intermittent Itraconazole in the Treatment of Dermatophyte Toenail Onychomycosis. Pharmacoeconomics, 2001, 19, 401-410.	1.7	16
58	The Cost Effectiveness of Tapered versus Abrupt Discontinuation of Oral Cyclosporin Microemulsion for the Treatment of Psoriasis. Pharmacoeconomics, 2001, 19, 599-608.	1.7	11
59	Morbidity and mortality in patients waiting for coronary artery bypass surgery. European Journal of Cardio-thoracic Surgery, 2001, 19, 260-265.	0.6	50